Penile Cancer
-
Genitourinary Cancer
Penile Cancer
-
VICCPHI25071
Phase 1 Study of EVOLVE104 in Advanced Urothelial & Squamous Cell Carcinomas
-
Eligibility Criteria:
Inclusion Criteria:
1. Histologically or cytologically confirmed diagnosis of any the following locally advanced or metastatic malignancies, relapsed from or refractory to prior therapies as listed below for each tumor type:
a. Urothelial/transitional cell or pure squamous cell carcinoma of the bladder.
b. SCC of the lung.
c. Cutaneous SCC.
d. Esophageal SCC.
e. SCC of the tongue.
f. Anogenital SCC, including penile, anal, vaginal, vulvar, cervical and urethral SCCs.
2. Able to provide a fresh tumor biopsy, if medically feasible and would not create undue risk for the subject, or an archival tissue preferably obtained within 6 months of study enrollment, or since the most recent progression.
Exclusion Criteria:
1. Presence of a mutation for which an approved targeted therapy is available and expected to provide a benefit, unless the subject refused or was deemed a poor candidate for such therapy by the investigator.
2. Prior therapy with a TCE.
FYI: Subjects will be hospitalized for 24-48 hours post-treatment for some doses.
For pre-screening, please contact: Message Basket: VICC RESEARCH PHASE 1
-
-